Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.
Petrie Flom: Looking Forward
February 7, 2017
Panelist: Bob Langer
Biologics present unique delivery challenges
• Small molecules vs biologics
• Unique challenges for biologics
• Thick solu...
Delivery-based solutions are broadly beneficial
Patients Providers Industry
Reduced administration costs
Improved access a...
Upcoming SlideShare
Loading in …5
×

Robert S. Langer, "Looking Forward"

218 views

Published on

February 7, 2017

Many of today’s important medications are biological products made from living organisms, manufactured through biotechnology, derived from natural sources, or produced synthetically. Biosimilars are a type of biological product approved by FDA on the basis of being highly similar to an already approved biological reference product.

This panel of experts discussed the current state of biosimilars in the healthcare ecosystem and what comes next from a technical and legal perspective. Topics included how the next generation of biosimilars could improve patient access to standard-of-care therapies, the concept of “biobetters,” economic and intellectual property considerations, and policy approaches to support existing and future biosimilars.

Learn more on our website: http://petrieflom.law.harvard.edu/events/details/looking-forward

Published in: Healthcare
  • Be the first to comment

  • Be the first to like this

Robert S. Langer, "Looking Forward"

  1. 1. Petrie Flom: Looking Forward February 7, 2017 Panelist: Bob Langer
  2. 2. Biologics present unique delivery challenges • Small molecules vs biologics • Unique challenges for biologics • Thick solution requires large volume doses • Inherently less stable than small molecules • Approaches to improve dosing • Drug-based • Change the drug itself, making a new drug • Delivery-based • Oral with additives to increase absorption • Oral - to be more constant • Topical with additives to increase skin permeability • Injectable – to last for a long time • Local – to reduce toxicity • Not all work for biologics • Need unique solutions designed for biologics • New “biobetter” technology • Additives thin drug solution • Enable reduced dose volume • Facilitate rapid home delivery • Use with biosimilars and other biologics http://drexelmedicine.org/patient-services/rheumatology/services/ http://www.huffingtonpost.com/2013/11/22/h5n1-bird- flu-vaccine-fda_n_4326148.html Small molecule Biologic Hospital infusion Injection
  3. 3. Delivery-based solutions are broadly beneficial Patients Providers Industry Reduced administration costs Improved access and convenience Increased compliance Improved efficacy No risks from drug development Faster to market than developing a new drug Platform technology Need policy in place to support all players before products reach market Improved safety

×